Hola,
Are you new here?

I have an account

Conecta con

+150K Projects

+300K Companies

+230 Financiaciones

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

CANDY

financed

Closed

Therapeutic discovery for cholangiocellular carcinoma

Cholangiocarcinoma (CCA) is one of the deadliest cancers comprising a heterogeneous cluster of malignancies that are distinct to hepatocellular carcinoma (HCC) and that can emerge at any point in the biliary tree. While not very c... see more

31/01/2024

INSERM

150K€

Project Budget: 150K€

Project leader

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2024-01-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSERM

150.00K€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 21 months Date Start: 2022-04-14
End date: 2024-01-31

Project leader

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 150K€

participation deadline Sin fecha límite de participación.

Project description Cholangiocarcinoma (CCA) is one of the deadliest cancers comprising a heterogeneous cluster of malignancies that are distinct to hepatocellular carcinoma (HCC) and that can emerge at any point in the biliary tree. While not very common, CCA is responsible for 2% of cancer-related deaths worldwide annually and rising. The incidence in European countries is increasing rapidly ranging from 1 to more than 4 cases/100,000. CCA is mostly diagnosed very late resulting in aggressive disease progression, poor treatment response, and dismal prognosis with a median survival of less than 2 years. Curative hepatic resection is an option in 10-30% cases and is mostly linked to recurrence within 12 months in over 50% of patients. For most patients, diagnosis will occur when the disease is already too advanced, and the only options are chemotherapies or palliative care. Current standard-of-care for CCA is unsatisfactory with very limited efficacy and adverse effects. Recently approved second-line therapeutics slightly improve outcome but are only suited to a small subset of CCA patients. Thus, there is a major unmet medical need for novel therapeutic strategies to improve patient outcome. Based on a robust data package obtained in a panel of CCA models within ERC HEPCIR, here we will explore the use of a novel class of compounds exploiting a unique and differentiated first-in-class mechanism-of-action and validate their efficacy in vivo as a first-line therapeutic for CCA. Proof-of-concept studies will be performed in state-of-the-art patient-derived models combined with scRNASeq and proteomics. The data obtained will serve as a pre-IND data package for this indication. An established collaboration with a pharma partner will ensure fast-track completion of the preclinical development towards IND. Collectively, ERC PoC CANDY will deliver completed proof-of-concept for a novel therapeutic approach for CCA which has the potential to transform patient care.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers

What is innovating.Works? Lose yourself in the best search engine for innovative companies you've ever seen, see how your competition is funded, connect with that partner you didn't know about, discover R&D projects that need you, and much, much more just a click away.

Smart Company-Financial Motor Innovating tiene un perfil tecnológico financiero de 400.000 empresas gracias al cual sabe a qué ayuda puede ir o no cualquier empresa de forma automática. Parece magia pero es tecnología.

Create your project and find partners ¿Tienes un proyecto y buscas un partner? Una Universidad, Centro Tecnológico, Consultoría? Este es tu sitio. Gracias al motor de búsqueda podemos recomendarte los mejores socios y ponerte en contacto con ellos.